High SLC7A11 levels in NPC cells led to reduced MHC-I antigen presentation by limiting TAP1 transcription and activating ERAD-dependent MHC-I degradation, which can hinder the recognition of cancer cells by the immune system. Here, SLC7A11 is linked to cancer.